Compounded hormones are custom-mixed hormone preparations made by specialized pharmacies rather than manufactured by pharmaceutical companies. They typically contain the same types of hormones used in standard hormone therapy (estrogen, progesterone, testosterone), but they’re blended to order in specific doses, combinations, or delivery forms based on a prescriber’s instructions. Unlike commercially manufactured hormone drugs, compounded hormones are not reviewed or approved by the FDA for safety and effectiveness.
These preparations are most commonly used for managing menopause symptoms, though they’re also prescribed for other hormonal needs. An estimated 7,500 pharmacies in the United States specialize in compounding, and hormones are among the most frequently compounded medications. Understanding how they differ from standard prescriptions, and what the tradeoffs are, matters if you or a provider is considering this option.
How Compounding Works
Traditional compounding has been part of pharmacy practice for centuries. The basic idea is straightforward: a pharmacist prepares a medication tailored to an individual patient when a commercially available product doesn’t meet their needs. A doctor writes a prescription specifying the hormone, the dose, and the delivery form, and the compounding pharmacy mixes it.
The appeal of compounded hormones is flexibility. Multiple hormones can be combined into a single preparation, something not always possible with off-the-shelf products. A common example is “Biest,” which blends two forms of estrogen into one cream or capsule. Compounding pharmacies also offer a wider range of dosage forms and strengths than what’s commercially available. You might get hormones as creams, gels, capsules, lozenges (called troches), vaginal inserts, or subcutaneous pellets implanted under the skin. Some of these delivery methods simply don’t exist in FDA-approved versions.
There are two categories of compounding pharmacies under federal law. Section 503A pharmacies fill individual prescriptions for specific patients and are primarily regulated by state pharmacy boards. Section 503B facilities, called outsourcing facilities, can produce larger batches without individual prescriptions and are registered with the FDA, giving them a layer of federal oversight that 503A pharmacies lack.
The “Bioidentical” Label
Compounded hormones are frequently marketed as “bioidentical,” meaning their molecular structure is identical to the hormones your body produces naturally. This is true of the hormones themselves, but the term can be misleading. Many FDA-approved hormone products also use bioidentical hormones. Commercially manufactured estradiol patches, progesterone capsules, and testosterone gels all contain hormones that are structurally identical to what the human body makes.
The American College of Obstetricians and Gynecologists (ACOG) has noted that compounding pharmacies often use “bioidentical” as a marketing term to suggest their products are more natural, safer, or more effective than standard prescriptions. There’s no evidence to support that claim. The real distinction between compounded and commercial hormone therapy isn’t the hormones themselves but how they’re made, tested, and regulated.
Why Doctors Sometimes Prescribe Them
There are legitimate clinical reasons for compounding. The most common is when a patient has an allergy or sensitivity to an inactive ingredient in a commercial product, such as a dye, preservative, or filler. Compounding allows the pharmacist to leave out the offending ingredient. Some patients can’t swallow pills and need a cream or lozenge instead, and the right combination may not exist commercially.
Certain compounded preparations also contain hormones that aren’t available in any FDA-approved product. Estriol, a weaker form of estrogen, and DHEA (a precursor hormone) are examples. If a prescriber wants to use one of these hormones, compounding is the only option. ACOG acknowledges that compounded medications “may be appropriate for some patients and in some circumstances,” particularly when commercially available products genuinely don’t meet a patient’s needs.
That said, for most patients seeking standard hormone therapy for menopause, an FDA-approved bioidentical product exists. The gap between what’s available commercially and what’s available through compounding has narrowed over the years, though compounded preparations still offer more dose granularity and more delivery options.
Safety and Quality Concerns
The central concern with compounded hormones is consistency. FDA-approved drugs go through rigorous manufacturing controls and batch testing to ensure every pill or patch delivers the labeled dose within a tight range. Compounded preparations don’t undergo this level of quality assurance. A limited FDA survey of compounded progesterone products found that 40% of samples failed repeat potency testing, meaning the actual hormone content didn’t reliably match what the label said. One in five samples also failed content uniformity testing, which means doses varied from one unit to the next within the same batch.
This isn’t a minor technicality. Getting too much or too little of a hormone can cause real problems: breakthrough bleeding, mood changes, or inadequate symptom relief on the low end, and increased health risks on the high end. Because compounded products aren’t manufactured under the same federal oversight as commercial drugs, there’s also less assurance about sterility and the absence of contaminants.
A major review by the National Academies of Sciences, Engineering, and Medicine (NASEM) examined the available evidence on compounded hormone therapy and found a near-total absence of rigorous clinical data. The safety and effectiveness information that did exist came mostly from anecdotal reports, patient testimonials, and prescriber observations rather than controlled studies. NASEM concluded that the widespread use of compounded hormones without this evidence “poses a public health concern.”
Missing Warnings and Oversight
FDA-approved hormone therapy products carry standardized patient information and a black box warning noting the risks of heart attack, stroke, blood clots, breast cancer, and dementia associated with certain hormone combinations. Compounded hormone preparations are not required to include these warnings, even though they contain the same active hormones and presumably carry similar risks.
The North American Menopause Society’s 2022 position statement specifically flagged this gap, citing “minimal government regulation and monitoring, overdosing and underdosing, presence of impurities and lack of sterility, lack of scientific efficacy and safety data, and lack of a label outlining risks” as safety concerns with compounded products. The absence of standardized labeling means patients using compounded hormones may not receive the same risk information that patients using commercial products automatically get.
Adverse event reporting is another weak spot. When an FDA-approved drug causes a problem, there’s a structured system for tracking it. The FDA has pushed for better adverse event reporting from compounding pharmacies, but the infrastructure is less developed, making it harder to detect safety signals.
What Major Medical Groups Recommend
ACOG, the Endocrine Society, and NAMS all agree on the core recommendation: FDA-approved hormone therapies should be used over compounded versions when an appropriate commercial product exists. These organizations don’t say compounded hormones should never be used. They say compounding should be reserved for situations where commercial products genuinely can’t meet a patient’s needs.
If you’re considering compounded hormones, the key questions to ask your prescriber are practical ones. Is there an FDA-approved product that would work for you? If not, what specifically about your situation makes compounding necessary? If the answer is an allergy, an unusual dosage requirement, or a hormone that isn’t commercially available, compounding serves a clear purpose. If the answer is primarily about the appeal of “natural” or “custom” therapy, the evidence doesn’t support that as a reason to bypass the safety infrastructure that comes with FDA-approved products.
For patients already using compounded hormones who want to explore switching, a prescriber familiar with both options can often identify a commercial bioidentical product that provides comparable treatment with the added assurance of standardized manufacturing and safety monitoring.